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Introduction
Case history 
A 29 year old man presented in August 2010 at with 3 month 
history of  abdominal pain, 3 week history of  testicular 
swelling and abdominal mass. He also reported  cough and 
weight loss. Patient had been working as water proofer for 
the last 8 years, single and fathers of  an 18 month old child. 
He has no family history of  malignancy, is a heavy drinker (45 
units per week) but non-smoker. On examination he looked 
wasted, in obvious pain, dyspneic with a respiratory rate 
of  40/min. He had cervical lymphadenopathy , moderate 
gynacomastia,  a central abdominal mass of  10×8 cm and 
right testicular mass. The chest had diffuse crepitations; the 
rest of  the examination was  unremarkable. Chest radiograph 
revealed diffuse widespread  infiltrates in both lung fields 
(See fig.1A).  The admitting  medical officer suspected TB. 
Sputum for AAFB was  negative and CT scan of  abdomen 
revealed para-aortic mass  measuring 9X12 cm (see fig.2A) 
with right hydronephrosis (see fig.3A), patient initially 
refused  hiv testing but at a later stage  tested positive using 
Unigold (rapid hiv -1 antibody test ), base-line CD4 count 
was 331 cells/μL, kidney function was normal, normal liver 
enzymes: ALP103.9iu/l, AST35.1iu/l, ALT9.1 iu/l, LDH 
2192.7. At one week from initial presentation, evaluation and 
consultation with the oncologist on  the clinical picture and 
results  changed the diagnosis of  TB and testicular cancer 
was suspected. We were unable to measure α-fetoprotein 
(AFP)and b-hCG at base-line ,further review of  the chest 
xray showed cannon ball in both lung fields. The findings 
of  a testicular mass, abdominal mass and cannon balls on 
the chest xray  were much more in keeping with a testicular 
cancer with metastases to the lungs . 
 (Figure 1A)
Fig: 1a Diffuse widespread infiltrates on both lung fields before 
chemotherapy
                                             (Figure 1B)
Fig: 1b Complete resolution of lesions in lung fields after 
chemotherapy
This is a Testicular cancer suspect with lung metastases 
initially thought to be TB  who refused an hiv test 
What would be your approach to management ?
Treatment
An orchidectomy of  the right testis was performed and 
histology  revealed yolk sac tumor which is a type of  a germ 
cell tumor (GCT). After the surgery, four cycles of  BEP 
(Bleomycin 30 IU weekly i.v, etoposide 100mg/m2 D1-5 p.o 
and cisplatin 20mg/m2 D1-D5 i.v) in 21 day cycles over a 
period of  3 months were given.  The hematological counts 
and renal function were closely monitored throughout his 
treatment. Whilst on treatment, he was transfused 3 units 
of  packed red cells and had a course of  granulocyte-colony 
stimulating factor (Filgrastim) to treat severe neutropenia . He 
had renal dysfunction on two occasions with his creatinine 
being 1.79mg/dl and 5mg/dl respectively. This prompted 
a delay of  cisplatin administration but not Bleomycin and 
etoposide, aggressive fluid diuresis and recommencing 
cisplatin only with normalization of  creatinine clearance. 
During the third BEP cycle  patient developed  malaria 
confirmed by blood film parasetemia of  2+. He was put on 
antimalarial treatment-Lumefantrine Artemether for three 
days to which he responded.   
 (Figure 2A)
Fig 2a abdominal bulky mass  measuring 9X12 cm before 
chemotherapy
Malawi Medical Journal; 23(3): 91-93 September 2011 Treatment of Metastatic turmour
                                                     (  Figure 2B)
Fig 2b Two masses showing tumor regression with central necrosis 
3x3cm & 3x2.5cm in size after chemo
The patient’s chemotherapy was delayed once for severe 
neutropenia. After 4 BEP cycles, patient had responded well 
to chemotherapy: abdominal mass was not palpable and had 
only a residual mass detectable on abdominal CT scan (Fig 
2b). Chest radiograph showed clearing of  cannon balls in 
lung fields (see fig.1b) and the abdominal CT scan findings 
of  tumor regression with central necrosis were consistent 
with remarkable response(see fig. 2b), beta-hCG was 11.1 
mIU/ml and AFP 24 ng/ml. In the course of  chemotherapy 
the patient subsequently accepted an HIV test,CD4 was 
as above . This same time cotrimoxazole prophylaxis was 
commenced.  Patient was stable, orchidectomy scar healed 
and was  commenced on Triomune (HAART) soon after 
finishing his chemotherapy due to delayed HIV testing.
Discussion
It is estimated that about 40% of  HIV infected patients will 
develop a malignancy at some point in their life1. Germ cell 
tumors are known to appear more frequently in HIV infected 
patients and with high HIV prevalence in Malawi, it is 
important to examine the management of  such malignancies. 
The exact management of  germ cell tumors in general in HIV 
patients remains an area of  uncertainty and is challenging. 
Three main reasons are suggested. First being HIV causing 
mortality due to opportunistic infections2. Secondly, HIV 
infected patients tolerate chemotherapy poorly resulting in 
dose reductions that entail lower response rates  which did 
not happen in our patient2. Thirdly, HIV patients have more 
aggressive tumors or intrinsic chemotherapy resistance.3,4,5 
Our patient presented with metastatic disease and bulky 
intra-abdominal nodes which under-pins aggressive 
disease in this group of  patients. Some reports suggests 
management of  such patients with concurrent HAART and 
chemotherapy to improve treatment effectiveness.6,7 The 
improved survival that ensures is probably due to decreased 
HIV related mortality and better chemotherapy tolerance8,2. 
However other studies suggest that HIV-positive patients 
do not have excess toxicity compared to historical HIV-
negative controls9,10,11.  This suggests that poor outcome in 
HIV infected GCT is a result of  HIV complications mostly 
opportunistic infections. 
BEP a well tolerated and effective first line treatment 
for metastatic germ cell tumors, more specifically 
seminomas,which offers good survival and prognosis  was 
used in this patient7. It is common for patients to have 
residual necrotic masses after chemotherapy for bulky 
disease, which was the case in our patient. It has been noted 
that complete responders may have such residual masses. A 
residual mass of  <3 cm and a poorly defined residual mass of  
≥3 cm can be observed, reserving intervention for recurrent 
or progressive disease. Well-defined residual masses of  ≥3 
cm should be resected because there is a 55% likelihood of  
persistent disease. There was no immediate indication to 
intervene in the residual necrotic mass in this patient that 
was about 3 cm.
In our patient, the respiratory symptomatology and CXR 
findings were initially mistaken for TB (See Fig1). It is not 
everything that looks like TB that is TB. Malignancies in a 
region that has high TB prevalence may easily be mistaken 
for TB as was this case. The patient was given cotrimoxazole 
prophylactic cover 480 mg twice a day, standard chemotherapy 
which was successfully delivered and a good treatment 
response obtained. This is more relevant in any setting 
where accessibility to ARVs is challenging because of  long 
waiting lists. Hence this strategy would allow the cancer 
treatment for GCT be delivered without being delayed by 
the wait for HAART commencement. According to WHO 
recommendation, if  the HIV test and base-line CD 4 count 
of  our patient (<350 cells/µL) was done before initiating 
chemotherapy, he would have qualified for HAART upfront. 
The refusal to test HIV offered a unique opportunity 
to observe a different strategy from the recommended 
concurrent approach of  HAART and chemotherapy. BEP 
still offered remarkable response in the patient despite HIV 
positivity,  being ARV naïve, advanced metastatic lung lesions 
and bulky abdominal disease(Compare Fig :2a and Fig :2b ).
However, despite the initial response to chemotherapy, the 
response was not durable as the patient suffered lung relapse 
5months after completion of  chemotherapy. This could be 
as a result of  initial high disease burden/bulky disease and 
aggressive disease in an HIV positive individual. The second 
explanation for this un-durable response may be the delays 
in delivering adequate doses of  chemotherapy due to the 
episode of  renal dysfunction and on another occasion due 
to neutropenia. 
         (Figure 3A)
 (Figure 3B)
Fig :3a hydronephrosis in right kidney before chemo                                
Fig :3b resolved hydronephrosis after treatment
We suggest not delaying BEP in those with CD 4 count 
<350until HAART commencement where HAART is 
difficult to access or patient fails to consent either for HIV 
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testing or initiating HAART itself. This case demonstrates 
it is feasible to deliver treatment using non-concurrent 
approach.
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Two scholarships available
Just a reminder that COPE member editors from developing countries can apply for one of 
two scholarships to attend the seminar and annual general meeting. The deadline for ap-
plications is Friday 13 January 2012.
This will cover two nights’ hotel accommodation in London and round-trip (economy 
class) airfare. Interested editors should send a short CV (no more than 4 pages) and letter 
of application explaining why they would benefit from attending this meeting to the COPE 
(http://www.publicationethics.org/cope-european-seminar-2012).
Registration
The COPE seminar will be held on Friday 16 March 2012 at the Charles Darwin House Confer-
ence Centre in London. The seminar is free for COPE members and £300 for non-members. 
Registration is via the COPE website (http://www.publicationethics.org/cope-european-
seminar-2012) and will close on 2 March 2012.
More details can be found on the website (http://www.publicationethics.org/cope-europe-
an-seminar-2012).
Poster submission
COPE also invites you to submit your research on publication ethics for presentation as a 
poster at the seminar. The topics considered will be publication ethics-oriented research 
or information about ethical policies, techniques, collaborations, and initiatives that COPE 
members and others attending the COPE seminar will be interested in learning about. COPE 
will assess submitted abstracts for quality, relevance and suitability for presentation at 
COPE’s seminar.
The deadline for abstract submissions is 27 January 2012.
